Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: improved financial metrics, optimistic guidance, and expanding market presence are positive, but offset by regulatory uncertainties, competitive pressures, and supply chain risks. The lack of a share repurchase program and unclear management responses in the Q&A session further contribute to a cautious outlook. With no new partnerships or strong catalysts, the stock is likely to remain stable, resulting in a neutral sentiment.
Revenue Q4 2024 $5.1 million, an increase of 5% compared to $4.8 million in Q4 2023.
Gross Profit Q4 2024 $2.7 million, with a gross margin of approximately 53%, compared to $2.4 million and a gross margin of 49% in Q4 2023. The increase was due to cost savings in supply chain and reduction in service costs.
Operating Expenses Q4 2024 $4.9 million, a 15% decrease from $5.8 million in Q4 2023, primarily due to a decrease in headcount, discretionary payroll, and consultant costs.
Net Loss Q4 2024 $3.4 million or $0.14 per share, compared to a net loss of $3.2 million or $0.22 per share in Q4 2023.
Cash Used in Operations Q4 2024 $1.4 million, down from $1.6 million in Q4 2023.
Revenue Full Year 2024 $17.9 million, down from $18.3 million in 2023, due to a difficult 2023 comparable driven by procurement cycles and the impact of COVID on fulfilling a $2 million pipeline.
Gross Profit Full Year 2024 $9.5 million, with a gross margin of approximately 53%, compared to $9.1 million and a gross margin of 50% in 2023, due to cost savings in supply chain and reduction in service costs.
Operating Expenses Full Year 2024 $20 million, a 17% decrease from $24.2 million in 2023, due to lower headcount and reduced discretionary payroll and consulting costs.
Net Loss Full Year 2024 $11.3 million or $0.56 per share, compared to a net loss of $15.2 million or $1.10 per share in 2023.
Cash Used in Operations Full Year 2024 $9.8 million, down from $12.1 million in 2023.
Cash and Restricted Cash as of December 31, 2024 $6.5 million.
Ekso Indego Personal: The company is focusing on the Ekso Indego Personal device, which received CMS pricing determination in Q2 2024, creating a significant opportunity for Medicare enrollees with spinal cord injuries.
New Distribution Partnership: National Seating & Mobility has been named the exclusive distributor for the Ekso Indego Personal device in the CRT industry, expanding access to the product.
Market Access Strategy: The company is establishing a go-to-market strategy to notify early physician and provider adopters of the new CMS benefit category for the Ekso Indego Personal.
DME Partnerships: Engaging PRIA Healthcare for reimbursement services and market access to navigate the complexities of coding, coverage, and payment.
Operational Efficiencies: Improvements in supply chain and inventory management have resulted in strong gross margins and reduced operating expenses.
Shift in Focus: The company is shifting its focus from enterprise health to personal health products, anticipating increased contributions from the Ekso Indego Personal in 2025.
Regulatory Issues: The company is navigating a new reimbursement environment established by CMS for the Ekso Indego Personal device, which presents both opportunities and uncertainties in terms of market access and claim submissions.
Market Access Challenges: Engaging PRIA Healthcare for reimbursement services indicates challenges in effectively commercializing the product and ensuring it reaches the intended beneficiaries.
Competitive Pressures: The need to establish a go-to-market strategy and engage with a network of neuro-rehabilitation partners suggests competitive pressures in the healthcare technology market.
Supply Chain Challenges: While the company reported improvements in supply chain efficiencies, the historical context of challenges in fulfilling a $2 million pipeline inherited from Parker Hannifin indicates ongoing supply chain risks.
Economic Factors: The overall economic environment and its impact on healthcare spending and reimbursement policies could affect the company's revenue growth and operational strategies.
Go-to-Market Strategy for Ekso Indego Personal: Establishing an effective market access function to operate within the CMS reimbursement environment, focusing on notifying early physician and provider adopters of the new CMS benefit category redetermination.
Partnership with PRIA Healthcare: Engaged PRIA Healthcare for reimbursement services and market access to navigate complexities of coding, coverage, and payment for Ekso Indego Personal.
Distribution Partnership with National Seating & Mobility: Named National Seating & Mobility as the exclusive distributor of the Personal device within the complex rehabilitation technology industry in the U.S.
Expansion of Distribution Network: Ramping up pilots and partnerships with regional and national DME suppliers to broaden access to Ekso Indego Personal.
Revenue Expectations for 2025: While the majority of revenue in 2025 will still come from enterprise, increased contribution from personal health products is anticipated.
Gross Margin Outlook: Gross margin is expected to continue trending up as 2025 progresses, despite potential quarter-over-quarter variability.
Claims Submission Timeline: Anticipate submitting claims to CMS for over 25 Medicare beneficiaries over the next six to nine months.
Share Repurchase Program: None
The earnings call highlighted several negative factors: a significant revenue decline, reduced gross profit and margins, and an increased net loss. The Q&A revealed deferred sales due to regulatory issues and uncertainty in Enterprise Health sales recovery. Despite some progress in the Indego Personal business and cost management efforts, the challenges in coding, coverage, and payment processes, alongside supply chain risks and AI integration uncertainties, contribute to a negative sentiment. The lack of clear guidance on grant reliance further exacerbates concerns, likely leading to a negative stock price reaction.
The earnings call presents a mixed picture: while there are positive developments such as improved cash position, strong gross margins, and strategic partnerships, there are also concerns about revenue decline, macroeconomic uncertainties, and reliance on enterprise health. The Q&A section did not alleviate these concerns, with management unable to provide clear guidance on certain issues. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the likely stock price movement is neutral, within the -2% to 2% range over the next two weeks.
The earnings call presents a mixed outlook. Positive aspects include improved gross margins and reduced operating expenses, along with optimistic guidance for multi-unit orders in North America. However, the company missed EPS expectations and faces regulatory and market access challenges, which could temper investor enthusiasm. The lack of a share repurchase program and unclear timelines for private payer engagement further contribute to a neutral sentiment. The company's financial performance shows slight improvement, but not enough to strongly impact the stock price positively or negatively.
The earnings call presents mixed signals: improved financial metrics, optimistic guidance, and expanding market presence are positive, but offset by regulatory uncertainties, competitive pressures, and supply chain risks. The lack of a share repurchase program and unclear management responses in the Q&A session further contribute to a cautious outlook. With no new partnerships or strong catalysts, the stock is likely to remain stable, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
